Vital Therapies (VTL) Shares Up 3.2%

Vital Therapies Inc (NASDAQ:VTL)’s share price shot up 3.2% during mid-day trading on Tuesday . The company traded as high as $0.34 and last traded at $0.32. 1,585,600 shares were traded during mid-day trading, a decline of 14% from the average session volume of 1,853,021 shares. The stock had previously closed at $0.31.

A number of brokerages recently issued reports on VTL. Cantor Fitzgerald lowered shares of Vital Therapies from an “overweight” rating to a “neutral” rating in a research report on Wednesday, September 12th. Raymond James lowered shares of Vital Therapies from an “outperform” rating to a “market perform” rating and set a $6.00 target price for the company. in a research report on Wednesday, September 12th. William Blair lowered shares of Vital Therapies from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 12th. ValuEngine lowered shares of Vital Therapies from a “buy” rating to a “hold” rating in a research report on Wednesday, September 12th. Finally, BidaskClub lowered shares of Vital Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, September 6th. Seven analysts have rated the stock with a hold rating, The stock currently has a consensus rating of “Hold” and a consensus price target of $12.00.

The stock has a market cap of $13.49 million, a PE ratio of -0.24 and a beta of 4.29.

Vital Therapies (NASDAQ:VTL) last announced its earnings results on Tuesday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.03. On average, sell-side analysts anticipate that Vital Therapies Inc will post -1.11 earnings per share for the current year.

In other news, Director Muneer A. Satter sold 447,500 shares of the firm’s stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $0.36, for a total transaction of $161,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Muneer A. Satter sold 11,382,277 shares of the firm’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $0.36, for a total transaction of $4,097,619.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,929,271 shares of company stock valued at $4,292,912. Insiders own 33.90% of the company’s stock.

Several large investors have recently bought and sold shares of VTL. Northern Trust Corp boosted its holdings in shares of Vital Therapies by 12.0% in the first quarter. Northern Trust Corp now owns 83,688 shares of the company’s stock worth $569,000 after buying an additional 8,993 shares during the period. TD Asset Management Inc. boosted its holdings in shares of Vital Therapies by 50.2% in the second quarter. TD Asset Management Inc. now owns 36,344 shares of the company’s stock worth $249,000 after buying an additional 12,144 shares during the period. Quantitative Systematic Strategies LLC acquired a new position in shares of Vital Therapies in the second quarter worth about $139,000. Rhumbline Advisers acquired a new position in shares of Vital Therapies in the second quarter worth about $183,000. Finally, Granahan Investment Management Inc. MA boosted its holdings in shares of Vital Therapies by 9.3% in the second quarter. Granahan Investment Management Inc. MA now owns 607,696 shares of the company’s stock worth $4,163,000 after buying an additional 51,484 shares during the period. Institutional investors own 32.89% of the company’s stock.

About Vital Therapies (NASDAQ:VTL)

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply